查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417486

下一代癌症診斷市場報告：至2030年的趨勢、預測和競爭分析

Next Generation Cancer Diagnostics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

下一代癌症診斷的趨勢和預測

到2030年，全球下一代癌症診斷市場預計將達到179億美元，2024年至2030年的年複合成長率為11.0%。該市場的主要驅動力是癌症疾病的盛行率不斷上升，對有效預後預測和早期檢測各種類型癌症的需求以及對有效診斷的需求不斷成長。主要相關人員擴大致力於創造新方法來全球下一代癌症診斷市場的未來前景廣闊，生物標記開發、CTC分析、蛋白質體分析、表觀遺傳分析和遺傳分析市場都有機會。

下一代癌症診斷市場洞察

Lucintel 預計，在預測期內，治療監測仍將是最大的區隔，因為癌症治療中免疫療法和標靶治療的普及增加了對有效治療監測的需求。

由於擁有強大的醫療保健系統和對癌症研究的高度重視，北美在預測期內可能仍然是最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，全球下一代癌症診斷市場預計將達到 179 億美元。

Q2.市場成長預測如何？

A2.下一代癌症診斷市場預計2024年至2030年年複合成長率為11.0%。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要促進因素是癌症疾病盛行率的不斷上升、對各種類型癌症的有效預後預測和早期檢測的需求以及對有效診斷的需求不斷成長。主要相關人員擴大努力創建解決問題的新方法

Q4.市場的主要細分市場是什麼？

A4.由於生物標記開發、CTC分析、蛋白質體分析、表觀磊晶分析和遺傳分析市場的機會，全球下一代癌症診斷市場的未來充滿希望。

Q5.市場上主要企業有哪些？

A5.下一代癌症診斷的主要企業如下。

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，在預測期內，治療監測仍將是其最大的區隔，因為癌症治療中免疫療法和標靶治療的普及增加了對有效治療監測的需求。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於其強大的醫療保健系統和對癌症研究的高度重視，預計北美在預測期內仍將是最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球下一代癌症診斷市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球下一代癌症診斷市場趨勢（2018-2023）與預測（2024-2030）
  • 按癌症類型分類的全球下一代癌症診斷市場
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 子宮頸癌
    • 其他
  • 依技術分類的全球下一代癌症診斷市場
    • 下一代定序
    • 定量 PCR 和多重檢測
    • 實驗室晶片和逆轉錄 PCR
    • 蛋白質微陣列
    • DNA微陣列
  • 依功能分類的全球下一代癌症診斷市場
    • 治療監測
    • 伴同性診斷
    • 預後
    • 癌症篩檢
    • 風險分析
  • 全球下一代癌症診斷市場（依應用）
    • 生物標記開發
    • CTC分析
    • 蛋白質體分析
    • 磊晶分析
    • 遺傳分析
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 依地區分類的全球下一代癌症診斷市場
  • 北美下一代癌症診斷市場
  • 歐洲下一代癌症診斷市場
  • 亞太地區下一代癌症診斷市場
  • 其他地區的下一代癌症診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按癌症類型分類的全球下一代癌症診斷市場成長機會
    • 依技術分類的全球下一代癌症診斷市場的成長機會
    • 依功能分類的全球下一代癌症診斷市場成長機會
    • 依應用分類的全球下一代癌症診斷市場成長機會
    • 依地區分類的全球下一代癌症診斷市場成長機會
  • 全球下一代癌症診斷市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球下一代癌症診斷市場的能力
    • 全球下一代癌症診斷市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare
簡介目錄

Next Generation Cancer Diagnostics Trends and Forecast

The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

A more than 150-page report is developed to help in your business decisions.

Next Generation Cancer Diagnostics by Segment

The study includes a forecast for the global next generation cancer diagnostics by cancer type, technology, function, application, and region.

Next Generation Cancer Diagnostics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

Next Generation Cancer Diagnostics Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Next-Generation Sequencing
  • qPCR & Multiplexing
  • Lab-On-A-Chip & Reverse Transcriptase-PCR
  • Protein Microarrays
  • DNA Microarrays

Next Generation Cancer Diagnostics Market by Function [Shipment Analysis by Value from 2018 to 2030]:

  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis

Next Generation Cancer Diagnostics Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Others

Next Generation Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Next Generation Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies next generation cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the next generation cancer diagnostics companies profiled in this report include-

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Next Generation Cancer Diagnostics Market Insights

Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Features of the Global Next Generation Cancer Diagnostics Market

Market Size Estimates: Next generation cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Next generation cancer diagnostics market size by various segments, such as by cancer type, technology, function, application, and region in terms of value ($B).

Regional Analysis: Next generation cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, technology, function, application, and regions for the next generation cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the next generation cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the next generation cancer diagnostics market size?

Answer: The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030.

Q2. What is the growth forecast for next generation cancer diagnostics market?

Answer: The global next generation cancer diagnostics market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the next generation cancer diagnostics market?

Answer: The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

Q4. What are the major segments for next generation cancer diagnostics market?

Answer: The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets.

Q5. Who are the key next generation cancer diagnostics market companies?

Answer: Some of the key next generation cancer diagnostics companies are as follows.

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6. Which next generation cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

Q7. In next generation cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the next generation cancer diagnostics market by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Next Generation Cancer Diagnostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Next Generation Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Breast Cancer
    • 3.3.3: Colorectal Cancer
    • 3.3.4: Cervical Cancer
    • 3.3.5: Others
  • 3.4: Global Next Generation Cancer Diagnostics Market by Technology
    • 3.4.1: Next-generation Sequencing
    • 3.4.2: qPCR & Multiplexing
    • 3.4.3: Lab-on-a-chip & Reverse Transcriptase-PCR
    • 3.4.4: Protein Microarrays
    • 3.4.5: DNA Microarrays
  • 3.5: Global Next Generation Cancer Diagnostics Market by Function
    • 3.5.1: Therapeutic Monitoring
    • 3.5.2: Companion Diagnostics
    • 3.5.3: Prognostics
    • 3.5.4: Cancer Screening
    • 3.5.5: Risk Analysis
  • 3.6: Global Next Generation Cancer Diagnostics Market by Application
    • 3.6.1: Biomarker Development
    • 3.6.2: CTC Analysis
    • 3.6.3: Proteomic Analysis
    • 3.6.4: Epigenetic Analysis
    • 3.6.5: Genetic Analysis
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Next Generation Cancer Diagnostics Market by Region
  • 4.2: North American Next Generation Cancer Diagnostics Market
    • 4.2.1: North American Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.2.2: North American Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.3: European Next Generation Cancer Diagnostics Market
    • 4.3.1: European Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.3.2: European Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.4: APAC Next Generation Cancer Diagnostics Market
    • 4.4.1: APAC Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.4.2: APAC Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.5: ROW Next Generation Cancer Diagnostics Market
    • 4.5.1: ROW Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.5.2: ROW Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Technology
    • 6.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Function
    • 6.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Application
    • 6.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Region
  • 6.2: Emerging Trends in the Global Next Generation Cancer Diagnostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Janssen Pharmaceuticals
  • 7.2: Illumina
  • 7.3: Novartis
  • 7.4: F. Hoffmann-La Roche
  • 7.5: Koninklijke Philips
  • 7.6: QIAGEN
  • 7.7: Agilent Technologies
  • 7.8: Abbott
  • 7.9: Thermo Fisher Scientific
  • 7.10: GE HealthCare